A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of dose regimens of ALX-0061
administered subcutaneously (s.c.) in combination with methotrexate (MTX) to subjects with
active rheumatoid arthritis (RA) despite MTX therapy, compared with placebo.
To assess the effects of ALX-0061 on quality of life, pharmacokinetics (PK), pharmacodynamics
(PD), and immunogenicity of ALX-0061, and to define the optimal dose regimen for ALX-0061,
based on safety and efficacy, for further clinical development.